GIST Support International - logo

GIST Support International - PF-04691502
GIST Imagery

PF-04691502

This drug under development by Pfizer Oncology is in a Phase I trial.

Mode of action:  this drug targets the PI3K / mTOR pathway.

Manufacturer:  under development by Pfizer Oncology
 

Current Clinical Trials relevant to GIST:

NCT00927823: A Trial To Assess Safety And Tolerability Of  PF-04691502 In Cancer Patients



back to top